Moleculin Q1 2023 Earnings Report
Key Takeaways
Moleculin Biotech reported its financial results for the quarter ended March 31, 2023. The company's cash and cash equivalents were $37.3 million as of March 31, 2023, sufficient to meet its projected operating requirements into the third quarter of 2024.
Completed the first cohort in the Phase 1b portion of its Phase 1b/2 trial evaluating Annamycin in combination with Cytarabine for AML treatment.
Announced presentation of positive pharmacokinetics and tissue-organ distribution data demonstrating high anti-tumor activity of Annamycin in preclinical cancer models.
Research and development expense was $5.7 million for the three months ended March 31, 2023.
Cash and cash equivalents of $37.3 million as of March 31, 2023, expected to fund operations into the third quarter of 2024.